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Multiple sclerosis (MS) is a neurodegenerative disorder characterized by an inflammatory autoimmune disease process in the central nervous system (CNS) (1). MS presents with clinical impairments based on location and severity of CNS lesions. Fatigue is the most common reported symptom
of people with MS (PwMS) (2), and 80–85% of individuals describe it as the most disabling feature of
the disease (3, 4). Decreased quality of life (5), limited physical activity (6, 7), and increased rates of
depression and anxiety (8, 9) are associated with higher levels of reported fatigue among PwMS. The
specific etiology of fatigue in MS is unknown, and it is likely the product of multiple factors rather
than a single cause (1).
There is a need for development of a unified taxonomy to help define what people experience when
they report fatigue (10, 11). An early attempt to define fatigue was published from the 1981 CIBA
Foundation Symposium in “Human Muscle Fatigue: Physiological Mechanisms” by Edwards (12) as
“a failure to maintain the required or expected force.” While Edwards provided a simple and direct
operational definition, it failed to convey subjective feelings described by PwMS. Enoka and Stuart
(13) expanded Edwards’ definition to include perception, stating that fatigue is “an acute impairment
of performance that includes both an increase in the perceived effort necessary to exert a desired
force and the eventual inability to produce this force.” This definition features Mosso’s dichotomy and
is now a commonly used framework within the realm of fatigue research (13). Within this taxonomy,
force decrements are considered distinct from sensations that arise from prolonged muscular activity. However, as investigators began to uncover multiple mechanistic causes for fatigue, they began to
label fatigue with descriptors consisting of the independent variables studied. Examples of this trend
include cognitive fatigue, peripheral fatigue, and central fatigue among others. Beyond cohesive
operational definitions, the limited ability to isolate components of Enoka and Stuart’s expanded
definition explains, in part, why so little progress has been made in addressing clinically reported
fatigue symptoms (14).
Kluger et al. (10) presented a taxonomy that attempts to reunite the developing silos of fatigue
work by returning to Enoka and Stuart’s definition. He calls for the common language of fatigue to
be divided into two well-defined categories, distinguishing between the perception of fatigue and
fatigability. “Perception of fatigue” defines subjective sensations related to an individual’s symptom
complaint and is the result of homeostatic and psychological factors. “Fatigability” relates to task
performance and is defined by a change in performance relative to an objective criterion. Enoka
and Duchateau (11) presented additional framework for viewing fatigue as a symptom that has a
trait characteristic and can be influenced by state variables. This view of fatigue allows researchers to
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measure the effects of short-term and modifiable state variables
on the long-term trait characteristic of fatigue (i.e., the perception
of fatigue or fatigability). The approach of Enoka and Duchateau
(11) encourages investigators to emphasize their assessment
methodology and the task dependency of fatigue, while minimizing use of obtuse modifiers or descriptors that lack clarity
and yield little insight into causative factors. Developing and
conceptualizing unified operational definitions of fatigue holds
ramifications for clinical practice. It is our view that a combination of poorly defined taxonomies, unknown etiology, and vague
clinical descriptions have made fatigue difficult to quantify during clinical assessment. Therefore, it is not surprising that current
treatments are non-specific and yield unsatisfactory outcomes.
The purpose of this paper is to convey the limitations of current
fatigue assessments for evaluating task performance fatigability
in rehabilitative settings for PwMS. Additionally, we call for the
development of clinical tests which can measure the influence of
state variables on the trait characteristic of performance fatigability as it relates to function and quality of life.

measuring fatigability requires careful consideration to develop
appropriate performance tasks and valid outcomes (10). Based
on this perspective, emphasis needs to be placed on developing
clinical assessments correlated with state variables of fatigability
to accurately evaluate the trait characteristic of fatigue’s influence
on an individual’s function, when determining independence or
recovery in PwMS.

ENHANCING FUNCTIONAL OUTCOMES
WITH CLINICAL FATIGABILITY
ASSESSMENT
Historically, PwMS were discouraged from participating in
regular exercise to avoid exacerbating fatigue (25). There has
been a paradigm shift in the last decade as exercise programs
for PwMS have demonstrated promising improvements in functional performance (26). A growing body of evidence suggests
that rehabilitative programs for PwMS may enhance quality of
life and contribute to maintaining independence throughout
the progression of the disease. Several interventions including a
resistance-training component, in particular, may be effective for
reducing both perceived fatigue and improving functional status
(15, 26). However, there is a lack of consensus on the most efficacious exercise modality and dosage for treating reported fatigue
in PwMS. Furthermore, it is the authors’ view that the failure to
include fatigability measures as the primary outcome in exercise
studies limits the ability to draw firm conclusions regarding the
efficacy of an exercise prescription on modifying state variables
related to performance fatigability in PwMS. This omission may
partially explain the limited adoption of strength training and
other modes of exercise as viable treatment options for fatigability
in PwMS (26).
Reframing how investigators characterize fatigue in MS may
guide subsequent research efforts within this area of inquiry.
Enoka and Duchateau (11) have proposed three levels of analysis
for measuring the impact of fatigability on human performance.
They propose first selecting a criterion measure of performance
modulated by fatigue and then identifying a laboratory test that
measures the performance of the criterion measure. Finally,
they suggest conducting studies to determine the significance
of adjustments to the modulating factors limiting performance
on the laboratory test (where the modulating factors are state
variables, and the reported symptom of fatigue relates to the trait
characteristic of the individual). In Figure 1, the authors present
a similar strategy that can be adopted for clinical measurement
as well.
In a rehabilitative setting, clinical assessments of fatigability
should be associated with functional tasks of daily living. Steens
et al. (24, 27) have begun to look at state characteristics of fatigability, including muscular strength and capacity (both criterion
measures of performance), which are associated with trait levels
of fatigue reported in PwMS. While it is helpful to understand
that state variables of fatigability relate to the overall trait of
fatigue, we still have limited knowledge about how these variables
are associated with clinical assessment measures. For example,
Steens’ observations did not include limb muscles that are more

THE LIMITATIONS OF SUBJECTIVE
ASSESSMENT IN CLINICAL
REHABILITATION ENVIRONMENTS
The fatigue severity scale (FSS) and fatigue impact scale (FIS) are
questionnaires of self-reported fatigue. Both tests are the current
primary clinical outcome measures for objectively measuring
fatigue symptoms in MS. For example, Latimer-Cheung et al.
(15) examined over 30 studies where at least one of these questionnaires was the primary outcome for measuring the impact
of exercise on fatigue. While self-reported fatigue remains an
important outcome, the use of the FSS and FIS involves limitations associated with questionnaires regarding regression to the
mean and response bias (16). Moreover, exercise-based interventions paradoxically show large changes in functional capacity
and independence with only mild to moderate changes in fatigue
questionnaire scores after skilled physical therapy including aerobic endurance training and progressive resistance training (17,
18). Scores on both the FSS and FIS correlate with disease severity
as determined by the extended disability status scale (EDSS) in
PwMS (19). However, the FSS and FIS do not adequately reflect
functional status established by clinical outcome measures such
as the 6-min walk test (20, 21), gait speed, or temporal and spatial
components of gait kinematics (22). Questionnaires may have
poor association with indices of whole muscle fatigue derived
from isometric muscle testing (18). The utility of self-reported
fatigue assessments may be constrained by the confounding of
qualitative complaints of fatigue by other MS impairments (23).
Steens et al. (24) found fatigability in PwMS explained variance
in FSS scores; however, more of the variance was explained when
adding depression to the regression. This exemplifies how a qualitative complaint or perception can influence subjective tests and
highlights the need for developing objective measures of fatigability. In our opinion, the need for outcome measures to separate
fatigability from the perception of fatigue is critical in clinical
practice environments such as rehabilitative medicine. Clinically
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and the Functional Capacity Test developed by Dalgas et al. (30).
These tests attempt to combine various repetitive tasks which
mimic daily function. However, it is our opinion that the validity
of these tests would be enhanced by better understanding their
association with trait characteristics of fatigue. The construct
validity of the aforementioned tests would be strengthened by
determining the relationship between the scores obtained from
these functional assessments and performance values from
various fatigue tests in both aerobic and anaerobic conditions.
This approach would better characterize how state variables
such as metabolic requirements or muscle actions would align
with task specificity measured within a clinic. Dalgas et al. (31)
state that limited existing literature on fatigability responses in
aerobic compared to anaerobic environments has made assessment of both endurance and strength exercise trials difficult.
Another outcome often overlooked when evaluating state variables of muscle performance is anaerobic recovery. Our view is
that further inquiry into anaerobic recovery relative to muscle
capacity could provide meaningful insights into how fatigability
affects temporal aspects of functional task performance. Such
information could help practitioners adjust exercise prescription
and monitor training adaptations.
Assessment of muscle morphology as a state variable may also
provide valuable insights concerning performance fatigability.
Previous work by Kent-Braun et al. (32) and Wens et al. (33)
highlight changes in muscle related to cross-sectional area, size,
composition, and fiber type in PwMS. Importantly, diminished
muscle cross-sectional area and greater levels of intramuscular
adipose tissue are associated with poor performance with repeated
or sustained functional tasks (34). While methods to characterize skeletal muscle are often invasive or difficult to implement in
rehabilitation settings (32, 35), alternative approaches involving
ultrasound have shown that proxy measures of muscle tissue
composition are also associated with impaired performance (36,
37). Further study regarding muscle morphology using clinically
viable methods may advance our understanding of the state variables of fatigability in MS.
Further evaluation of the impact of modulating state variables
on fatigability in clinical rehabilitation settings will be challenging. The current trend of measuring multiple state variables of
fatigue at once has masked the clinically significant changes
that can occur through interventions (15). However, building a
consensus regarding a unified fatigue taxonomy, and the further
development of standardized methods to assess state variables of
fatigability, will advance the larger goal of implementing effective
rehabilitation treatment for MS-related fatigue.

Figure 1 | Hierarchy chart depicting the general steps for
associating clinical assessments of fatigability with overall fatigue in
individuals with MS. Self-reported measures of perceived fatigue do not
consistently correspond to performance-based measures of fatigability. Valid
functional measures of fatigue must be associated with accepted estimates
of fatigability and viable for use in rehabilitation settings. Better understanding
of the relationship between the performance-based criterion measures and
the trait characteristic of fatigability may aid our approach to the assessment
and treatment of those people with multiple sclerosis. Notes: *Examples of
criterion measures include the duration of task sustainability, rate of change in
force production, power, voluntary activation, reaction times, heart rate, mean
arterial pressure, core temperature, and outcomes of muscle morphology.
†
Examples of functional performance tests include the Adult Myopathy
Assessment Test (AMAT), Short Physical Performance Battery Protocol
(SPPB), and Dalgas’ Functional Capacity Test (FCT). ‡Examples of state
variables include the exercise prescription, modality of exercise, and exercise
environment. §Examples of intervention to manipulate a state variable: a
progressive resistance exercise program or an aerobic endurance exercise
program.

likely to mimic functional task requirements and mobility in MS.
Little is known about the relationship between state variables of
MS-related fatigue and the performance of limb musculature
involved in tasks such as walking, which is heavily evaluated as a
functional outcome related to independence in this population.
Our stance is that the development of clinical assessments,
which manipulate state variables under fatiguing tasks, is the
most direct way to evaluate the trait characteristic of fatigue on
functional performance. Of key importance is designing tests
which can best mimic functional requirements of daily living.
Current functional exams of performance in MS are not strongly
associated with fatigue as a trait characteristic (20–22). Tests
which may hold promise include the Short Physical Performance
Battery Protocol (28), Adult Myopathy Assessment Tool (29),
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CONCLUSION
Fatigue is a vague symptom that defies simple characterization.
Due to this ambiguity, there is a need for quantifiable clinical
measures of performance fatigability as they relate to the rehabilitation of PwMS. Assessing fatigability may be critical for
understanding the relationship between an individual’s function
and reported fatigue symptoms. Performance-based fatigability
testing provides an in-depth view of muscle function as a state
variable related to activities of daily living and mobility. With
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focused clinical testing, rehabilitation professionals can track the
response to interventions and make recommendations on specific
exercise prescriptions for PwMS. Taking these steps will help clinicians guide PwMS toward the goals of minimizing debilitating
fatigue, improving functional performance, and enhancing their
quality of life.
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